Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Inflammation and anti-inflammatory treatments might influence the risk of diabetes. The objective of this study was to assess factors associated with incident diabetes in rheumatoid arthritis (RA). METHODS: The study population consisted of RA patients from a multi-center cohort study, Corrona. To assess risk associated with disease modifying antirheumatic drug (DMARD) exposure, we assessed five mutually exclusive DMARD groups. Additionally, we assessed the risk associated with body mass index (BMI, <25, 25-30, >30 kg/m2) and glucocorticoid usage. Incident cases of diabetes were confirmed through adjudication, and Cox regression models were fit to estimate the risk of incident diabetes. RESULTS: We identified 21,775 DMARD treatment regimens, the mean (SD) age at the index visit was 58 (13) years, disease duration 10 (10) years, and 30% used oral glucocorticoids at the time. Eighty-four incident cases of diabetes were confirmed within the treatment exposure periods. The hazard ratio (HR, 95% confidence interval) for diabetes was significantly reduced in patients receiving TNF inhibitors, HR 0.35 (0.13, 0.91), compared to patients treated with non-biologic DMARDs other than hydroxychloroquine and methotrexate. Hydroxychloroquine, methotrexate and use of other biologic DMARDs had a numerically reduced risk compared to the same group. Patients prescribed ≥7.5 mg of glucocorticoids had a HR of 2.33 (1.68, 3.22) of incident diabetes compared with patients not prescribed oral glucocorticoids. RA patients with a BMI >30 had a HR of 6.27 (2.97, 13.25) compared to patients with BMI ≤25. CONCLUSION: DMARDs, glucocorticoids and obesity influenced the risk of incident diabetes in a large cohort of RA patients. Monitoring for the occurrence of diabetes should be part of routine RA management with a focus on specific subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577 · cited 2×
“Diabetes increases the risk of cardiovascular disease, blindness, kidney failure and lower-limb amputation, and causes substantial morbidity and mortality in affected individuals [4].”
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 1×
“Blockade of interleukin-1 with the drug anakinra has been shown to improve glycemia and beta-cell secretory function in patients with type 2 diabetes [12].”
BackgroundAgca, R., Heslinga, S. C., Rollefstad, S., Heslinga, M., McInnes, I. B., Peters, M. J. L., Kvien, T. K., Dougados, M., Radner, H., Atzeni, F., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209775 · Cited by 1,380
Greenberg, J. D., Kremer, J. M., Curtis, J. R., Hochberg, M. C., Reed, G., Tsao, P., Farkouh, M. E., Nasir, A., Setoguchi, S., & Solomon, D. H. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.129916 · Cited by 350
Self-citationden Uyl, D., van Raalte, D. H., Nurmohamed, M. T., Lems, W. F., Bijlsma, J. W. J., Hoes, J. N., Dijkmans, B. A. C., & Diamant, M. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33378 · Cited by 70
Cited by
C-reactive protein and implications in rheumatoid arthritis and associated comorbidities
Pope, J. E., & Choy, E. H. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.11.005 · Cited by 320
Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases
Hardy, R. S., Raza, K., & Cooper, M. S. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0371-y · Cited by 265
Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment
Wu, D., Luo, Y., Li, T., Zhao, X., Lv, T., Fang, G., Ou, P., Li, H., Luo, X., Huang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1051082 · Cited by 263
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Eiers, A.-K., Vettorazzi, S., & Tuckermann, J. P. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-225371 · Cited by 31
Metadata
- Authors
- Lillegraven, S., Greenberg, J. D., Reed, G. W., Saunders, K., Curtis, J. R., Harrold, L., Hochberg, M. C., Pappas, D. A., Kremer, J. M., & Solomon, D. H.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-01-23
- Volume
- 14
- Issue
- 1
- Pages
- e0210459
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2913685322
- Cited by
- 54
- References
- 5
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. https://app.cochat.ai/papers/10.1371/journal.pone.0210459
- The paper
- Lillegraven, S., Greenberg, J. D., Reed, G. W., Saunders, K., Curtis, J. R., Harrold, L., Hochberg, M. C., Pappas, D. A., Kremer, J. M., & Solomon, D. H. (2019). Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLOS ONE. https://doi.org/10.1371/journal.pone.0210459
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.